(4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-ylamino)acetic acid methyl ester | 889673-42-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-ylamino)acetic acid methyl ester
• 英文别名: methyl 2-[(4-oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)amino]acetate
• CAS: 889673-42-1
• 化学式: C₂₁H₁₇N₃O₃S
• 分子量: 391.45
• InChiKey: IMKBDUWNQVGQRI-UHFFFAOYSA-N

物化性质

• 沸点：
  565.1±60.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-ylamino)acetic acid methyl ester 在 肼 作用下， 以 乙醇 为溶剂， 生成 (4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-ylamino)acetic acid hydrazide
  参考文献：
  名称：

  Structure–activity relationship study of novel tissue transglutaminase inhibitors

  摘要：

  Thieno[2,3-d]pyrimidin-4-one acylhydrazide derivatives were discovered as moderately potent inhibitors of TGase 2 (tissue transglutaminase) utilizing a fluorescence-based assay that measured TGase 2 catalyzed incorporation of the dansylated Lys derivative alpha-N-Boc-Lys-CH2-CH2-dansyl into the protein substrate N,N-dimethylated-casein. A SAR study revealed that the acylhydrazide thioether side-chain and the thiophene ring were critical to inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.005
• 作为产物：
  描述：

  2-氨基-4-苯基噻吩-3-羧酸乙酯 在 吡啶 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙醇 、 乙腈 为溶剂， 反应 1.0h， 生成 (4-oxo-3,5-diphenyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-ylamino)acetic acid methyl ester
  参考文献：
  名称：

  Structure–activity relationship study of novel tissue transglutaminase inhibitors

  摘要：

  Thieno[2,3-d]pyrimidin-4-one acylhydrazide derivatives were discovered as moderately potent inhibitors of TGase 2 (tissue transglutaminase) utilizing a fluorescence-based assay that measured TGase 2 catalyzed incorporation of the dansylated Lys derivative alpha-N-Boc-Lys-CH2-CH2-dansyl into the protein substrate N,N-dimethylated-casein. A SAR study revealed that the acylhydrazide thioether side-chain and the thiophene ring were critical to inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.005

文献信息

• Tissue transglutaminase inhibitors
  申请人：Stein L. Ross

  公开号：US20060183759A1

  公开（公告）日：2006-08-17

  The present invention provides novel compounds and methods useful for treating transglutaminase associated disorders such as celiac spru, Alzheimer's disease and Huntington's disease. Certain compounds of the invention are tissue transglutaminase inhibitors that comprise thiophene moieties. Methods of the invention include treatment of transglutaminase associated disorders with inhibitors of transglutaminase.

  本发明提供了一种治疗转酰胺酶相关疾病的新化合物和方法，例如腹泻性脆皮病、阿尔茨海默病和亨廷顿病。本发明的某些化合物是组织转酰胺酶抑制剂，包括噻吩基团。本发明的方法包括使用转酰胺酶抑制剂治疗转酰胺酶相关疾病。
• WO2006/60702
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TRANSGLUTAMINASE TISSULAIRE
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2006060702A1

  公开（公告）日：2006-06-08

  [EN] The present invention provides novel compounds and methods useful for treating transglutaminase associated disorders such as celiac spru, Alzheimer's disease and Huntington's disease. Certain compounds of the invention are tissue transglutaminase inhibitors that comprise thiophene moieties. Methods of the invention include treatment of transglutaminase associated disorders with inhibitors of transglutaminase.
  [FR] L'invention concerne de nouveaux composés et méthodes permettant de traiter des troubles associés à la transglutaminase, tels que la maladie coeliaque, la maladie d'Alzheimer et la maladie de Huntington. Certains composés selon l'invention possèdent des inhibiteurs de la transglutaminase tissulaire qui comprennent des fractions thiophène. Des méthodes selon l'invention comprennent le traitement des troubles associés à la transglutaminase à l'aide des inhibiteurs de la transglutaminase.